Katrine Bosley is CEO of Cambridge-based Editas, one of the best-funded biotech startups developing medical therapies using a new gene-editing technology called CRISPR. Backed by Bill Gates, Google Ventures, and a who’s who of the VC world, Editas raised more than $94 million in its January 2016 IPO. Editas aims to launch clinical trials of gene-based treatments for hereditary blindness as early as 2017, with other therapies to follow, including cancer immunotherapies developed in collaboration with Seattle-based Juno Therapeutics. But it faces competition from Intellia and CRISPR Therapeutics, among others, and could be adversely affected by an ongoing U.S. Patent Office review of rights to key CRISPR patents. A graduate of Cornell University with a degree in biology, Bosley has a long resume on the business side of biotech. As CEO of Avila Therapeutics, she led the company in successfully developing a new type of oncology drug, and an acquisition by Celgene.